EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that it has sold 1,675,000 ordinary shares in Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) at a price of £4.60 per ordinary share, in response to strong institutional demand. The sale has resulted in gross proceeds of £7.705m to EKF and generated a profit of over £5.6m after dealing expenses.
Following this transaction EKF will continue to hold 1,002,981 ordinary shares in Renalytix AI plc.
EKF Diagnostics Holdings plc
Christopher Mills, Non-Executive Chairman
Julian Baines, CEO
Richard Evans, FD and COO
Tel: 00 44 29 2071 0570
|N+1 Singer (Nomad & Broker)
Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance)
Tom Salvesen (Corporate Broking)
|Tel: 020 7496 3000
Walbrook PR Limited
|Tel: 020 7933 8780 or
Mob: 07980 541 893 / 07584 391 303